| Basics |
Ocular Therapeutix, Inc.
Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
|
| IPO Date: |
July 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.68B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 3.18%
|
| Avg Daily Range (30 D): |
$0.24 | 2.04%
|
| Avg Daily Range (90 D): |
$0.29 | 2.45%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.82M |
| Avg Daily Volume (30 D): |
2.02M |
| Avg Daily Volume (90 D): |
2.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
130 |
| Avg Trade Size (Sh.) (30 D): |
87 |
| Avg Trade Size (Sh.) (90 D): |
89 |
| Institutional Trades |
| Total Inst.Trades: |
1,337 |
| Avg Inst. Trade: |
$1.98M |
| Avg Inst. Trade (30 D): |
$2.36M |
| Avg Inst. Trade (90 D): |
$2.98M |
| Avg Inst. Trade Volume: |
.2M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.14M |
| Avg Closing Trade (30 D): |
$3.72M |
| Avg Closing Trade (90 D): |
$4.59M |
| Avg Closing Volume: |
219.55K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.38
|
$-.39
|
|
Diluted EPS
|
|
$-.38
|
$-.39
|
|
Revenue
|
$
|
$ 14.54M
|
$ 13.46M
|
|
Gross Profit
|
$
|
$ 12.77M
|
$ 11.52M
|
|
Net Income / Loss
|
$
|
$ -69.42M
|
$ -67.81M
|
|
Operating Income / Loss
|
$
|
$ -68.7M
|
$ -67.64M
|
|
Cost of Revenue
|
$
|
$ 1.77M
|
$ 1.94M
|
|
Net Cash Flow
|
$
|
$ -46.36M
|
$ 41.45M
|
|
PE Ratio
|
|
|
|
|
|
|
